|
| | 100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018 SB0702 Introduced 1/30/2017, by Sen. Kyle McCarter SYNOPSIS AS INTRODUCED: |
| 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 |
|
Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: U-47700) as a Schedule I controlled substance. Effective immediately.
|
| |
| | | CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY | |
| | A BILL FOR |
|
|
| | SB0702 | | LRB100 07354 RLC 17417 b |
|
|
1 | | AN ACT concerning criminal law.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Controlled Substances Act is |
5 | | amended by changing Section 204 as follows: |
6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
7 | | Sec. 204. (a) The controlled substances listed in this |
8 | | Section are
included in Schedule I. |
9 | | (b) Unless specifically excepted or unless listed in |
10 | | another
schedule, any of the following opiates, including their |
11 | | isomers,
esters, ethers, salts, and salts of isomers, esters, |
12 | | and ethers,
whenever the existence of such isomers, esters, |
13 | | ethers and salts is
possible within the specific chemical |
14 | | designation: |
15 | | (1) Acetylmethadol; |
16 | | (1.1) Acetyl-alpha-methylfentanyl |
17 | | (N-[1-(1-methyl-2-phenethyl)-
|
18 | | 4-piperidinyl]-N-phenylacetamide); |
19 | | (2) Allylprodine; |
20 | | (3) Alphacetylmethadol, except
|
21 | | levo-alphacetylmethadol (also known as levo-alpha-
|
22 | | acetylmethadol, levomethadyl acetate, or LAAM); |
23 | | (4) Alphameprodine; |
|
| | SB0702 | - 2 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (5) Alphamethadol; |
2 | | (6) Alpha-methylfentanyl
|
3 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
4 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
5 | | propanilido) piperidine; |
6 | | (6.1) Alpha-methylthiofentanyl
|
7 | | (N-[1-methyl-2-(2-thienyl)ethyl-
|
8 | | 4-piperidinyl]-N-phenylpropanamide); |
9 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
10 | | (7.1) PEPAP
|
11 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
12 | | (8) Benzethidine; |
13 | | (9) Betacetylmethadol; |
14 | | (9.1) Beta-hydroxyfentanyl
|
15 | | (N-[1-(2-hydroxy-2-phenethyl)-
|
16 | | 4-piperidinyl]-N-phenylpropanamide); |
17 | | (10) Betameprodine; |
18 | | (11) Betamethadol; |
19 | | (12) Betaprodine; |
20 | | (13) Clonitazene; |
21 | | (14) Dextromoramide; |
22 | | (15) Diampromide; |
23 | | (16) Diethylthiambutene; |
24 | | (17) Difenoxin; |
25 | | (18) Dimenoxadol; |
26 | | (19) Dimepheptanol; |
|
| | SB0702 | - 3 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (20) Dimethylthiambutene; |
2 | | (21) Dioxaphetylbutyrate; |
3 | | (22) Dipipanone; |
4 | | (23) Ethylmethylthiambutene; |
5 | | (24) Etonitazene; |
6 | | (25) Etoxeridine; |
7 | | (26) Furethidine; |
8 | | (27) Hydroxpethidine; |
9 | | (28) Ketobemidone; |
10 | | (29) Levomoramide; |
11 | | (30) Levophenacylmorphan; |
12 | | (31) 3-Methylfentanyl
|
13 | | (N-[3-methyl-1-(2-phenylethyl)-
|
14 | | 4-piperidyl]-N-phenylpropanamide); |
15 | | (31.1) 3-Methylthiofentanyl
|
16 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
|
17 | | 4-piperidinyl]-N-phenylpropanamide); |
18 | | (32) Morpheridine; |
19 | | (33) Noracymethadol; |
20 | | (34) Norlevorphanol; |
21 | | (35) Normethadone; |
22 | | (36) Norpipanone; |
23 | | (36.1) Para-fluorofentanyl
|
24 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
25 | | 4-piperidinyl]propanamide); |
26 | | (37) Phenadoxone; |
|
| | SB0702 | - 4 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (38) Phenampromide; |
2 | | (39) Phenomorphan; |
3 | | (40) Phenoperidine; |
4 | | (41) Piritramide; |
5 | | (42) Proheptazine; |
6 | | (43) Properidine; |
7 | | (44) Propiram; |
8 | | (45) Racemoramide; |
9 | | (45.1) Thiofentanyl
|
10 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
|
11 | | 4-piperidinyl]-propanamide); |
12 | | (46) Tilidine; |
13 | | (47) Trimeperidine; |
14 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
|
15 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
16 | | N-phenylpropanamide). |
17 | | (c) Unless specifically excepted or unless listed in |
18 | | another
schedule, any of the following opium derivatives, its |
19 | | salts, isomers
and salts of isomers, whenever the existence of |
20 | | such salts, isomers and
salts of isomers is possible within the |
21 | | specific chemical designation: |
22 | | (1) Acetorphine; |
23 | | (2) Acetyldihydrocodeine; |
24 | | (3) Benzylmorphine; |
25 | | (4) Codeine methylbromide; |
26 | | (5) Codeine-N-Oxide; |
|
| | SB0702 | - 5 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (6) Cyprenorphine; |
2 | | (7) Desomorphine; |
3 | | (8) Diacetyldihydromorphine (Dihydroheroin); |
4 | | (9) Dihydromorphine; |
5 | | (10) Drotebanol; |
6 | | (11) Etorphine (except hydrochloride salt); |
7 | | (12) Heroin; |
8 | | (13) Hydromorphinol; |
9 | | (14) Methyldesorphine; |
10 | | (15) Methyldihydromorphine; |
11 | | (16) Morphine methylbromide; |
12 | | (17) Morphine methylsulfonate; |
13 | | (18) Morphine-N-Oxide; |
14 | | (19) Myrophine; |
15 | | (20) Nicocodeine; |
16 | | (21) Nicomorphine; |
17 | | (22) Normorphine; |
18 | | (23) Pholcodine; |
19 | | (24) Thebacon. |
20 | | (d) Unless specifically excepted or unless listed in |
21 | | another
schedule, any material, compound, mixture, or |
22 | | preparation which contains
any quantity of the following |
23 | | hallucinogenic substances, or which
contains any of its salts, |
24 | | isomers and salts of isomers, whenever the
existence of such |
25 | | salts, isomers, and salts of isomers is possible
within the |
26 | | specific chemical designation (for the purposes of this
|
|
| | SB0702 | - 6 - | LRB100 07354 RLC 17417 b |
|
|
1 | | paragraph only, the term "isomer" includes the optical, |
2 | | position and
geometric isomers): |
3 | | (1) 3,4-methylenedioxyamphetamine
|
4 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
|
5 | | methylenedioxyamphetamine, MDA); |
6 | | (1.1) Alpha-ethyltryptamine
|
7 | | (some trade or other names: etryptamine;
|
8 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
9 | | 3-(2-aminobutyl)indole; a-ET; and AET); |
10 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); |
11 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
12 | | (also known as: N-ethyl-alpha-methyl-
|
13 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
14 | | and MDEA); |
15 | | (2.2) N-Benzylpiperazine (BZP); |
16 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); |
17 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
18 | | (4) 3,4,5-trimethoxyamphetamine (TMA); |
19 | | (5) (Blank); |
20 | | (6) Diethyltryptamine (DET); |
21 | | (7) Dimethyltryptamine (DMT); |
22 | | (7.1) 5-Methoxy-diallyltryptamine; |
23 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
24 | | (9) Ibogaine (some trade and other names:
|
25 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
26 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
|
| | SB0702 | - 7 - | LRB100 07354 RLC 17417 b |
|
|
1 | | indole; Tabernanthe iboga); |
2 | | (10) Lysergic acid diethylamide; |
3 | | (10.1) Salvinorin A; |
4 | | (10.5) Salvia divinorum (meaning all parts of the plant |
5 | | presently classified
botanically as Salvia divinorum, |
6 | | whether growing or not, the
seeds thereof, any extract from |
7 | | any part of that plant, and every compound,
manufacture, |
8 | | salts, isomers, and salts of
isomers whenever the existence |
9 | | of such salts, isomers, and salts of
isomers is possible |
10 | | within the specific chemical designation, derivative, |
11 | | mixture, or preparation of that plant, its
seeds or |
12 | | extracts);
|
13 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
14 | | (12) Peyote (meaning all parts of the plant presently |
15 | | classified
botanically as Lophophora williamsii
Lemaire, |
16 | | whether growing or not, the
seeds thereof, any extract from |
17 | | any part of that plant, and every compound,
manufacture, |
18 | | salts, derivative, mixture, or preparation of that plant, |
19 | | its
seeds or extracts); |
20 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); |
21 | | (14) N-methyl-3-piperidyl benzilate; |
22 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
23 | | (also known as N-hydroxy-alpha-methyl-
|
24 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
25 | | (15) Parahexyl; some trade or other names:
|
26 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
|
| | SB0702 | - 8 - | LRB100 07354 RLC 17417 b |
|
|
1 | | dibenzo (b,d) pyran; Synhexyl; |
2 | | (16) Psilocybin; |
3 | | (17) Psilocyn; |
4 | | (18) Alpha-methyltryptamine (AMT); |
5 | | (19) 2,5-dimethoxyamphetamine
|
6 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
7 | | (20) 4-bromo-2,5-dimethoxyamphetamine
|
8 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
9 | | 4-bromo-2,5-DMA); |
10 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
11 | | Some trade or other names: 2-(4-bromo-
|
12 | | 2,5-dimethoxyphenyl)-1-aminoethane;
|
13 | | alpha-desmethyl DOB, 2CB, Nexus; |
14 | | (21) 4-methoxyamphetamine
|
15 | | (4-methoxy-alpha-methylphenethylamine;
|
16 | | paramethoxyamphetamine; PMA); |
17 | | (22) (Blank); |
18 | | (23) Ethylamine analog of phencyclidine.
|
19 | | Some trade or other names:
|
20 | | N-ethyl-1-phenylcyclohexylamine,
|
21 | | (1-phenylcyclohexyl) ethylamine,
|
22 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
23 | | (24) Pyrrolidine analog of phencyclidine. Some trade |
24 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
25 | | PHP; |
26 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
|
| | SB0702 | - 9 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (26) 2,5-dimethoxy-4-ethylamphetamine
|
2 | | (another name: DOET); |
3 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
4 | | (another name: TCPy); |
5 | | (28) (Blank); |
6 | | (29) Thiophene analog of phencyclidine (some trade
|
7 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
8 | | 2-thienyl analog of phencyclidine; TPCP; TCP); |
9 | | (30) Bufotenine (some trade or other names:
|
10 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
11 | | 3-(2-dimethylaminoethyl)-5-indolol;
|
12 | | 5-hydroxy-N,N-dimethyltryptamine;
|
13 | | N,N-dimethylserotonin; mappine); |
14 | | (31) 1-Pentyl-3-(1-naphthoyl)indole |
15 | | Some trade or other names: JWH-018; |
16 | | (32) 1-Butyl-3-(1-naphthoyl)indole |
17 | | Some trade or other names: JWH-073; |
18 | | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- |
19 | | (2-iodophenyl)methanone |
20 | | Some trade or other names: AM-694; |
21 | | (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
22 | | (2-methyloctan-2-yl)phenol |
23 | | Some trade or other names: CP 47,497 |
24 | | and its C6, C8 and C9 homologs; |
25 | | (34.5) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- |
26 | | (2-methyloctan-2-yl)phenol), where side chain n=5; |
|
| | SB0702 | - 10 - | LRB100 07354 RLC 17417 b |
|
|
1 | | and homologues where side chain n=4, 6, or 7; Some |
2 | | trade or other names: CP 47,497; |
3 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
4 | | (2-methyloctan-2-yl)-6a,7, |
5 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol |
6 | | Some trade or other names: HU-210; |
7 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
8 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
9 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, |
10 | | salts, and salts of isomers; Some trade or other |
11 | | names: HU-210, Dexanabinol; |
12 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
13 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- |
14 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
15 | | Some trade or other names: HU-211; |
16 | | (37) (2-methyl-1-propyl-1H-indol- |
17 | | 3-yl)-1-naphthalenyl-methanone |
18 | | Some trade or other names: JWH-015; |
19 | | (38) 4-methoxynaphthalen-1-yl- |
20 | | (1-pentylindol-3-yl)methanone |
21 | | Some trade or other names: JWH-081; |
22 | | (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole |
23 | | Some trade or other names: JWH-122; |
24 | | (40) 2-(2-methylphenyl)-1-(1-pentyl- |
25 | | 1H-indol-3-yl)-ethanone |
26 | | Some trade or other names: JWH-251; |
|
| | SB0702 | - 11 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (41) 1-(2-cyclohexylethyl)-3- |
2 | | (2-methoxyphenylacetyl)indole |
3 | | Some trade or other names: RCS-8, BTW-8 and SR-18; |
4 | | (42) Any compound structurally derived from |
5 | | 3-(1-naphthoyl)indole or 1H-indol-3-yl- |
6 | | (1-naphthyl)methane by substitution at the |
7 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
8 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
9 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
10 | | or 2-(4-morpholinyl)ethyl whether or not further |
11 | | substituted in the indole ring to any extent, whether |
12 | | or not substituted in the naphthyl ring to any extent. |
13 | | Examples of this structural class include, but are |
14 | | not limited to, JWH-018, AM-2201, JWH-175, JWH-184, |
15 | | and JWH-185; |
16 | | (43) Any compound structurally derived from |
17 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
18 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
19 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
20 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
21 | | or 2-(4-morpholinyl)ethyl, whether or not further |
22 | | substituted in the pyrrole ring to any extent, whether |
23 | | or not substituted in the naphthyl ring to any extent. |
24 | | Examples of this structural class include, but are not |
25 | | limited to, JWH-030, JWH-145, JWH-146, JWH-307, and |
26 | | JWH-368; |
|
| | SB0702 | - 12 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (44) Any compound structurally derived from |
2 | | 1-(1-naphthylmethyl)indene by substitution |
3 | | at the 3-position of the indene ring by alkyl, haloalkyl, |
4 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
5 | | halide, alkyl aryl halide, 1-(N-methyl- |
6 | | 2-piperidinyl)methyl, or 2-(4- |
7 | | morpholinyl)ethyl whether or not further substituted in |
8 | | the indene ring to any extent, whether or not substituted |
9 | | in the naphthyl ring to any extent. Examples of |
10 | | this structural class include, but are not |
11 | | limited to, JWH-176; |
12 | | (45) Any compound structurally derived from |
13 | | 3-phenylacetylindole by substitution at the |
14 | | nitrogen atom of the indole ring with alkyl, haloalkyl, |
15 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
16 | | halide, alkyl aryl halide, 1-(N-methyl-2- |
17 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
18 | | whether or not further substituted in the indole ring |
19 | | to any extent, whether or not substituted in the phenyl |
20 | | ring to any extent. Examples of this structural |
21 | | class include, but are not limited to, JWH-167, |
22 | | JWH-250, JWH-251, and RCS-8; |
23 | | (46) Any compound structurally derived from |
24 | | 2-(3-hydroxycyclohexyl)phenol by substitution |
25 | | at the 5-position of the phenolic ring by alkyl, |
26 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
|
| | SB0702 | - 13 - | LRB100 07354 RLC 17417 b |
|
|
1 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
2 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
3 | | whether or not substituted in the cyclohexyl ring to any |
4 | | extent. Examples of this structural class |
5 | | include, but are not limited to, CP 47, |
6 | | 497 and its C8 homologue (cannabicyclohexanol); |
7 | | (46.1) Benzoylindoles: Any compound |
8 | | containing a 3-(benzoyl) indole structure with |
9 | | substitution at the nitrogen atom of the |
10 | | indole ring by an alkyl, haloalkyl, alkenyl, |
11 | | cycloalkylmethyl, cycloalkylethyl, |
12 | | 1-(N-methyl-2-piperidinyl)methyl, |
13 | | or 2-(4-morpholinyl)ethyl group |
14 | | whether or not further substituted |
15 | | in the indole ring to any extent and |
16 | | whether or not substituted in the phenyl ring |
17 | | to any extent. Examples of this structural class |
18 | | include, but are not limited , to , AM-630, |
19 | | AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
20 | | (47) 3,4-Methylenedioxymethcathinone |
21 | | Some trade or other names: Methylone; |
22 | | (48) 3,4-Methyenedioxypyrovalerone |
23 | | Some trade or other names: MDPV; |
24 | | (49) 4-Methylmethcathinone |
25 | | Some trade or other names: Mephedrone; |
26 | | (50) 4-methoxymethcathinone; |
|
| | SB0702 | - 14 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (51) 4-Fluoromethcathinone; |
2 | | (52) 3-Fluoromethcathinone; |
3 | | (53) 2,5-Dimethoxy-4-(n)-propylthio- |
4 | | phenethylamine; |
5 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; |
6 | | (55) Pentedrone; |
7 | | (56) 4-iodo-2,5-dimethoxy-N-((2-methoxy |
8 | | phenyl)methyl)-benzeneethanamine |
9 | | (trade or other name: 25I-NBOMe); |
10 | | (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) |
11 | | methyl]-benzeneethanamine (trade or other name: |
12 | | 25C-NBOMe); |
13 | | (58) 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) |
14 | | methyl]-benzeneethanamine (trade or other name: |
15 | | 25B-NBOMe); |
16 | | (59) 3-cyclopropoylindole with |
17 | | substitution at the nitrogen atom of the |
18 | | indole ring by alkyl, haloalkyl, alkenyl, |
19 | | cycloalkylmethyl, cycloalkylethyl, aryl |
20 | | halide, alkyl aryl halide, |
21 | | 1-(N-methyl-2-piperidinyl)methyl, or |
22 | | 2-(4-morpholinyl)ethyl, whether or not |
23 | | further substituted on the indole ring |
24 | | to any extent, whether or not substituted |
25 | | on the cyclopropyl ring to any extent: |
26 | | including , but not limited to , XLR11, |
|
| | SB0702 | - 15 - | LRB100 07354 RLC 17417 b |
|
|
1 | | UR144, FUB-144; |
2 | | (60) 3-adamantoylindole with |
3 | | substitution at the nitrogen atom of the |
4 | | indole ring by alkyl, haloalkyl, alkenyl, |
5 | | cycloalkylmethyl, cycloalkylethyl, |
6 | | aryl halide, alkyl aryl halide, |
7 | | 1-(N-methyl-2-piperidinyl)methyl, or |
8 | | 2-(4-morpholinyl)ethyl, whether or not |
9 | | further substituted on the indole ring to |
10 | | any extent, whether or not substituted on |
11 | | the adamantyl ring to any extent: including , |
12 | | but not limited to , AB-001; |
13 | | (61) N-(adamantyl)-indole-3-carboxamide |
14 | | with substitution at the nitrogen atom of the |
15 | | indole ring by alkyl, haloalkyl, alkenyl, |
16 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, |
17 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, |
18 | | or 2-(4-morpholinyl)ethyl, whether or not further |
19 | | substituted on the indole ring to any extent, whether |
20 | | or not substituted on the adamantyl ring to any |
21 | | extent: including , but not limited to , |
22 | | APICA/2NE-1, STS-135; |
23 | | (62) N-(adamantyl)-indazole-3-carboxamide |
24 | | with substitution at a nitrogen atom of the indazole |
25 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
26 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
|
| | SB0702 | - 16 - | LRB100 07354 RLC 17417 b |
|
|
1 | | 1-(N-methyl-2-piperidinyl)methyl, or |
2 | | 2-(4-morpholinyl)ethyl, whether or not further |
3 | | substituted on the indazole ring to any extent, |
4 | | whether or not substituted on the adamantyl |
5 | | ring to any extent: including , but not limited |
6 | | to , AKB48, 5F-AKB48; |
7 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl |
8 | | ester with substitution at the nitrogen atom of the |
9 | | indole ring by alkyl, haloalkyl, alkenyl, |
10 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
11 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
12 | | 2-(4-morpholinyl)ethyl, whether or not further |
13 | | substituted on the indole ring to any extent, |
14 | | whether or not substituted on the quinoline ring |
15 | | to any extent: including , but not limited to , PB22, |
16 | | 5F-PB22, FUB-PB-22; |
17 | | (64) 3-(1-naphthoyl)indazole with |
18 | | substitution at the nitrogen atom of the |
19 | | indazole ring by alkyl, haloalkyl, |
20 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, |
21 | | aryl halide, alkyl aryl halide, |
22 | | 1-(N-methyl-2-piperidinyl)methyl, or |
23 | | 2-(4-morpholinyl)ethyl, whether or not further |
24 | | substituted on the indazole ring to any extent, |
25 | | whether or not substituted on the naphthyl ring |
26 | | to any extent: including , but not limited to , |
|
| | SB0702 | - 17 - | LRB100 07354 RLC 17417 b |
|
|
1 | | THJ-018, THJ-2201; |
2 | | (65) 2-(1-naphthoyl)benzimidazole with |
3 | | substitution at the nitrogen atom of the benzimidazole |
4 | | ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
5 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
6 | | 1-(N-methyl-2-piperidinyl)methyl, or |
7 | | 2-(4-morpholinyl)ethyl, whether or not further |
8 | | substituted on the benzimidazole ring to any extent, |
9 | | whether or not substituted on the naphthyl ring to |
10 | | any extent: including, but not limited to , FUBIMINA; |
11 | | (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) |
12 | | -1H-indazole-3-carboxamide with substitution on the |
13 | | nitrogen atom of the indazole ring by alkyl, |
14 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
15 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
16 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
17 | | whether or not further substituted on the indazole |
18 | | ring to any extent: including , but not limited to , |
19 | | AB-PINACA, AB-FUBINACA, AB-CHMINACA; |
20 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan- |
21 | | 2-yl)-1H-indazole-3-carboxamide with substitution |
22 | | on the nitrogen atom of the indazole ring by alkyl, |
23 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
24 | | aryl halide, alkyl aryl halide, 1-(N-methyl-2- |
25 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether |
26 | | or not further substituted on the indazole ring to any |
|
| | SB0702 | - 18 - | LRB100 07354 RLC 17417 b |
|
|
1 | | extent: including , but not limited to , |
2 | | ADB-PINACA, ADB-FUBINACA; |
3 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- |
4 | | 1H-indole-3-carboxamide with substitution on the nitrogen |
5 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, |
6 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl |
7 | | aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
8 | | 2-(4-morpholinyl)ethyl, whether or not further |
9 | | substituted on the indole ring to any extent: |
10 | | including , but not limited to , ADBICA, 5F-ADBICA; |
11 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- |
12 | | 1H-indole-3-carboxamide with substitution on the |
13 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
14 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
15 | | halide, alkyl aryl halide, 1-(N-methyl-2- |
16 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
17 | | whether or not further substituted on the indole |
18 | | ring to any extent: including , but not limited |
19 | | to , ABICA, 5F-ABICA; |
20 | | (70) Methyl 2-(1H-indazole-3-carboxamido)- |
21 | | 3-methylbutanoate with substitution on the nitrogen |
22 | | atom of the indazole ring by alkyl, haloalkyl, |
23 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl |
24 | | halide, alkyl aryl halide, 1-(N-methyl-2- |
25 | | piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, |
26 | | whether or not further substituted on the indazole |
|
| | SB0702 | - 19 - | LRB100 07354 RLC 17417 b |
|
|
1 | | ring to any extent: including , but not |
2 | | limited to , AMB, 5F-AMB ; . |
3 | | (71) 3,4-Dichloro-N-[2-(dimethylamino) |
4 | | cyclohexyl]-N-methylbenzamide (Some trade or other |
5 | | name: U-47700). |
6 | | (e) Unless specifically excepted or unless listed in |
7 | | another
schedule, any material, compound, mixture, or |
8 | | preparation which contains
any quantity of the following |
9 | | substances having a depressant effect on
the central nervous |
10 | | system, including its salts, isomers, and salts of
isomers |
11 | | whenever the existence of such salts, isomers, and salts of
|
12 | | isomers is possible within the specific chemical designation: |
13 | | (1) mecloqualone; |
14 | | (2) methaqualone; and |
15 | | (3) gamma hydroxybutyric acid. |
16 | | (f) Unless specifically excepted or unless listed in |
17 | | another schedule,
any material, compound, mixture, or |
18 | | preparation which contains any quantity
of the following |
19 | | substances having a stimulant effect on the central nervous
|
20 | | system, including its salts, isomers, and salts of isomers: |
21 | | (1) Fenethylline; |
22 | | (2) N-ethylamphetamine; |
23 | | (3) Aminorex (some other names:
|
24 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
25 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
26 | | salts, optical isomers, and salts of optical isomers; |
|
| | SB0702 | - 20 - | LRB100 07354 RLC 17417 b |
|
|
1 | | (4) Methcathinone (some other names:
|
2 | | 2-methylamino-1-phenylpropan-1-one;
|
3 | | Ephedrone; 2-(methylamino)-propiophenone;
|
4 | | alpha-(methylamino)propiophenone; N-methylcathinone;
|
5 | | methycathinone; Monomethylpropion; UR 1431) and its
|
6 | | salts, optical isomers, and salts of optical isomers; |
7 | | (5) Cathinone (some trade or other names:
|
8 | | 2-aminopropiophenone; alpha-aminopropiophenone;
|
9 | | 2-amino-1-phenyl-propanone; norephedrone); |
10 | | (6) N,N-dimethylamphetamine (also known as:
|
11 | | N,N-alpha-trimethyl-benzeneethanamine;
|
12 | | N,N-alpha-trimethylphenethylamine); |
13 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
14 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
15 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV). |
16 | | (g) Temporary listing of substances subject to emergency |
17 | | scheduling.
Any material, compound, mixture, or preparation |
18 | | that contains any quantity
of the following substances: |
19 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
20 | | (benzylfentanyl), its optical isomers, isomers, salts,
|
21 | | and salts of isomers; |
22 | | (2) N-[1(2-thienyl)
|
23 | | methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
|
24 | | its optical isomers, salts, and salts of isomers. |
25 | | (h) Synthetic cathinones. Unless specifically excepted, |
26 | | any chemical compound not including bupropion, structurally |
|
| | SB0702 | - 21 - | LRB100 07354 RLC 17417 b |
|
|
1 | | derived from 2-aminopropan-1-one by substitution at the |
2 | | 1-position with either phenyl, naphthyl, or thiophene ring |
3 | | systems, whether or not the compound is further modified in one |
4 | | or more of the following ways: |
5 | | (1) by substitution in the ring system to |
6 | | any extent with alkyl, alkylenedioxy, alkoxy, |
7 | | haloalkyl, hydroxyl, or halide substituents, whether |
8 | | or not further substituted in the ring system |
9 | | by one or more other univalent substituents. |
10 | | Examples of this class include, but are not |
11 | | limited to, 3,4-Methylenedioxycathinone |
12 | | (bk-MDA); |
13 | | (2) by substitution at the 3-position |
14 | | with an acyclic alkyl substituent. Examples of |
15 | | this class include, but are not limited to, |
16 | | 2-methylamino-1-phenylbutan-1-one |
17 | | (buphedrone); or |
18 | | (3) by substitution at the 2-amino nitrogen |
19 | | atom with alkyl, dialkyl, benzyl, or methoxybenzyl |
20 | | groups, or by inclusion of the 2-amino nitrogen atom |
21 | | in a cyclic structure. Examples of this class include, |
22 | | but are not limited to, Dimethylcathinone, Ethcathinone, |
23 | | and a-Pyrrolidinopropiophenone (a-PPP). |
24 | | (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised |
25 | | 10-25-16.)
|
26 | | Section 99. Effective date. This Act takes effect upon |